SCHEMBL5482811

SCHEMBL5482811

CCn1c(CCC2=CNN(c3cccc(Cl)c3)O2)nnc1-c1ccco1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.38
TSHR P16473 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 7/20 0.36
KMT2A Q03164 7/20 0.36
PKM P14618 3/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
HTT P42858 1/20 0.36
POLB P06746 5/20 0.35
HPGD P15428 3/20 0.35
MCL1 Q07820 1/20 0.35
HSD17B10 Q99714 2/20 0.34
RECQL P46063 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TP53 P04637 1/20 0.34
USP2 O75604 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1544409 0.72 ANO1 (0.42) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL4944624 0.64 RAB9A (0.53) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL20021736 0.63 ALDH1A1 (0.55) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL1544537 0.62 ANO1 (0.44) ALDH1A1TSHRSMN1; SMN2KMT2APKM
SCHEMBL1544448 0.61 ALDH1A1 (0.52) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL15983758 0.60 ALDH1A1 (0.65) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL1544695 0.60 MEN1 (0.59) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL1544692 0.60 KCNH2 (0.41) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL5542199 0.60 HTR3E (0.40) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL1544335 0.59 MEN1 (0.58) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179188-A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179188-A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists GRM5, GRIK5, GRM2 ALDH1A1 4066/4885TSHR 847/4885SMN1; SMN2 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.